356 results on '"Granberg, Dan"'
Search Results
2. 630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study
3. Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours
4. Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours
5. Neuroendocrine Tumors of the Lung
6. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
7. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases
8. A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N
9. Metastatic Pheochromocytomas and Abdominal Paragangliomas
10. EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
11. A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
12. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region
13. Appendiceal Adenocarcinoids with Peritoneal Carcinomatosis Treated with Cytoreductive Surgery and Intraperitoneal Chemotherapy: A Retrospective Study of In Vitro Drug Sensitivity and Survival
14. MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours
15. Biochemical Testing in Patients with Neuroendocrine Tumors
16. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy : Analysis of Outcome, Safety and Their Determinants
17. Metastases from Neuroendocrine Tumors to the Breast Are More Common than Previously Thought. A Diagnostic Pitfall?
18. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
19. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines
20. Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors
21. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years
22. Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing
23. Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors: Analysis of the Phase 3, Randomized, Placebo-Controlled RADIANT-2 Study
24. A Randomized Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) To Assess Patient Preference for Lanreotide Autogel Given by Self/Partner or Given by Healthcare Professional
25. Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma
26. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants
27. Neuroendocrine tumours
28. Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE
29. Bronchial carcinoids
30. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3 : a multicenter cohort study
31. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3:a multicenter cohort study
32. Octreoscan in patients with bronchial carcinoid tumours
33. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors
34. Prognostic Markers in Patients with Typical Bronchial Carcinoid Tumors*
35. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.
36. Plasma Chromogranin A in Patients with Multiple Endocrine Neoplasia Type 1
37. Bronchial carcinoids
38. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
39. Kidney dosimetry during (177)Lu-DOTATATE therapy in patients with neuroendocrine tumors : aspects on calculation and tolerance
40. Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving 177Lu-DOTATATE therapy
41. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs) : feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
42. Selected For Oral Presentation: Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms : A Retrospective International Multicenter Study
43. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis : Results From the First Global Survey of Patients With NETs
44. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas : Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.
45. Gender-related differences in absorbed dose to risk organs in patients receiving Lu-177-Octreotate therapy
46. Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion : a retrospective study
47. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors
48. Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance
49. Serotonin, ATRX and DAXX as differential diagnostic markers of neuroendocrine tumours (NETs) in the sellar region. An immunohistochemical study in a large series of pituitary adenomas and in a non-pituitary NET
50. Neuroendocrine tumors with syndromic vasoactive intestinal polypeptide hypersecretion: a retrospective study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.